Evidence map›Paper›PMID 30574163›Full record

ReviewFrontiers in genetics2018

Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation.

Radha D Singh, Ruchita Shandilya, Arpit Bhargava, Rajat Kumar, Rajnarayan Tiwari, Koel Chaudhury, Rupesh K Srivastava, Irina Y Goryacheva, Pradyumna K Mishra

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Quantum Dots-Based Protocols for the Detection of RNAs.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Radha D SinghDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Ruchita ShandilyaDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Arpit BhargavaDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Rajat KumarDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Rajnarayan TiwariDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Koel ChaudhurySchool of Medical Science and Technology, Indian Institute of Technology, Kharagpur, India.
Rupesh K SrivastavaDepartment of Biotechnology, All India Institute of Medical Sciences, New Delhi, India.
Irina Y GoryachevaDepartment of General and Inorganic Chemistry, Saratov State University, Saratov, Russia.
Pradyumna K MishraDepartment of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most frequently occurring malignancy and the leading cause of cancer-related death for men in our country. The only recommended screening method is clinic based low-dose computed tomography (also called a low-dose CT scan, or LDCT). However, the effect of LDCT on overall mortality observed in lung cancer patients is not statistically significant. Over-diagnosis, excessive cost, risks associated with radiation exposure, false positive results and delay in the commencement of the treatment procedure questions the use of LDCT as a reliable technique for population-based screening. Therefore, identification of minimal-invasive biomarkers able to detect malignancies at an early stage might be useful to reduce the disease burden. Circulating nucleic acids are emerging as important source of information for several chronic pathologies including lung cancer. Of these, circulating cell free miRNAs are reported to be closely associated with the clinical outcome of lung cancer patients. Smaller size, sequence homology between species, low concentration and stability are some of the major challenges involved in characterization and specific detection of miRNAs. To circumvent these problems, synthesis of a quantum dot based nano-biosensor might assist in sensitive, specific and cost-effective detection of differentially regulated miRNAs. The wide excitation and narrow emission spectra of these nanoparticles result in excellent fluorescent quantum yields with a broader color spectrum which make them ideal bio-entities for fluorescence resonance energy transfer (FRET) based detection for sequential or simultaneous study of multiple targets. In addition, photo-resistance and higher stability of these nanoparticles allows extensive exposure and offer state-of-the art sensitivity for miRNA targeting. A major obstacle for integrating QDs into clinical application is the QD-associated toxicity. However, the use of non-toxic shells along with surface modification not only overcomes the toxicity issues, but also increases the ability of QDs to quickly detect circulating cell free miRNAs in a non-invasive mode. The present review illustrates the importance of circulating miRNAs in lung cancer diagnosis and highlights the translational prospects of developing QD-based nano-biosensor for rapid early disease detection.

Indexed as

circulating miRNAscirculating nucleic acidsenvironmental healthlung cancernanobiosensorquantum dotstranslational medicinetranslational research

Identifiers

PMID30574163
PMCPMC6291444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.